Note: Ingredients listed on restricted chemical lists
EC/CAS
206-019-2/288-32-4
Name of the chemical
Imidazol (2015/1221)
Concentration
>=1-<3%
General Information
Version
6.5
Revision date
2023-12-01
Product name
Hsp90a Active human
1.2.2. Uses advised against
For R&D use only. Not for pharmaceutical, household or other uses
Emergency telephone
+44 (0)870 8200418
Icons in SDS
Company Information
company name
Merck Life Science UK Limited
e-mail address of the competent person responsible for the Safety Data Sheet
TechnicalService@merckgroup.com
GHS Information
Signal word
Danger
Hazard Codes
Hazard statements (CLP)
H315, H319, H360D
Hazard statements
Code
Statements
H315
Causes skin irritation
Section 2
SECTION 2: Hazards identification
2.2 Label elements
Labelling
Signal word
Danger Danger
Hazard statements
H315 Causes skin irritation. H319 Causes serious eye irritation. H360D May damage the unborn child. Reduced Labeling (<= 125 ml) H360D May damage the unborn child.
Precautionary statements
P201 Obtain special instructions before use. P302 + P352 IF ON SKIN: Wash with plenty of water. P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. P308 + P313 IF exposed or concerned: Get medical advice/ attention. P201 Obtain special instructions before use. P308 + P313 IF exposed or concerned: Get medical advice/ attention.
Supplemental label elements
none none
2.3 Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
ECOLOGICAL INFORMATION
The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.
TOXICOLOGICAL INFORMATION
The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.
